{"title":"胃癌中B-Catenin和E-Cadherin表达的预后意义。","authors":"Sarra Ben Rejeb, Abir Labadi, Marwa Lakhal, Khadija Bellil, Adnen Chouchen","doi":"10.1080/15321819.2025.2505033","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Gastric cancer (GC) is a leading cause of cancer-related mortality worldwide. Dysregulation of molecular pathways, including β-Catenin-mediated Wnt signaling, epithelial-to-mesenchymal transition (EMT), and E-Cadherin-modulated cell adhesion, plays critical roles in gastric carcinogenesis. This study assesses the expression patterns of β-Catenin and E-Cadherin in GC and explores their prognostic significance.</p><p><strong>Methods: </strong>This retrospective, multi-center study analyzed GC cases diagnosed between 2009 and 2019 at the pathology departments of Security Forces and Rabta Hospitals. Tissue microarray (TMA) paraffin blocks from 48 GC cases were immunohistochemically stained using antibodies for β-Catenin (Leica, 17C2) and E-Cadherin (Leica, 36B5). β-Catenin expression was scored as membranous, cytoplasmic, or nuclear, with overexpression defined as ≥ 50% positive cells. E-Cadherin staining was categorized from absent (score 0) to marked membranous staining (score 3), with scores 0-2 considered aberrant. Statistical analysis was performed using SPSS version 23.</p><p><strong>Results: </strong>Of the 48 cases, β-Catenin overexpression was observed in 50% of cases, significantly associated with tumor differentiation (<i>p</i> = 0.033), age > 60 years (<i>p</i> = 0.042), and male sex (<i>p</i> = 0.028). Aberrant E-Cadherin expression was found in 65% of cases, linked to poorly cohesive and diffuse subtypes (<i>p</i> = 0.053), poor differentiation (<i>p</i> = 0.042), and recurrence (<i>p</i> = 0.043), with a trend toward reduced survival (<i>p</i> = 0.056).</p><p><strong>Conclusion: </strong>β-Catenin overexpression and aberrant E-Cadherin expression are frequent in GC, reflecting their roles in tumor progression via Wnt signaling and EMT. These findings highlight their potential as prognostic biomarkers and therapeutic targets, particularly for Wnt pathway-directed therapies in personalized GC management.</p>","PeriodicalId":15990,"journal":{"name":"Journal of immunoassay & immunochemistry","volume":" ","pages":"1-14"},"PeriodicalIF":0.0000,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prognostic significance of B-Catenin and E-Cadherin expression in gastric carcinoma.\",\"authors\":\"Sarra Ben Rejeb, Abir Labadi, Marwa Lakhal, Khadija Bellil, Adnen Chouchen\",\"doi\":\"10.1080/15321819.2025.2505033\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Gastric cancer (GC) is a leading cause of cancer-related mortality worldwide. Dysregulation of molecular pathways, including β-Catenin-mediated Wnt signaling, epithelial-to-mesenchymal transition (EMT), and E-Cadherin-modulated cell adhesion, plays critical roles in gastric carcinogenesis. This study assesses the expression patterns of β-Catenin and E-Cadherin in GC and explores their prognostic significance.</p><p><strong>Methods: </strong>This retrospective, multi-center study analyzed GC cases diagnosed between 2009 and 2019 at the pathology departments of Security Forces and Rabta Hospitals. Tissue microarray (TMA) paraffin blocks from 48 GC cases were immunohistochemically stained using antibodies for β-Catenin (Leica, 17C2) and E-Cadherin (Leica, 36B5). β-Catenin expression was scored as membranous, cytoplasmic, or nuclear, with overexpression defined as ≥ 50% positive cells. E-Cadherin staining was categorized from absent (score 0) to marked membranous staining (score 3), with scores 0-2 considered aberrant. Statistical analysis was performed using SPSS version 23.</p><p><strong>Results: </strong>Of the 48 cases, β-Catenin overexpression was observed in 50% of cases, significantly associated with tumor differentiation (<i>p</i> = 0.033), age > 60 years (<i>p</i> = 0.042), and male sex (<i>p</i> = 0.028). Aberrant E-Cadherin expression was found in 65% of cases, linked to poorly cohesive and diffuse subtypes (<i>p</i> = 0.053), poor differentiation (<i>p</i> = 0.042), and recurrence (<i>p</i> = 0.043), with a trend toward reduced survival (<i>p</i> = 0.056).</p><p><strong>Conclusion: </strong>β-Catenin overexpression and aberrant E-Cadherin expression are frequent in GC, reflecting their roles in tumor progression via Wnt signaling and EMT. These findings highlight their potential as prognostic biomarkers and therapeutic targets, particularly for Wnt pathway-directed therapies in personalized GC management.</p>\",\"PeriodicalId\":15990,\"journal\":{\"name\":\"Journal of immunoassay & immunochemistry\",\"volume\":\" \",\"pages\":\"1-14\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-05-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of immunoassay & immunochemistry\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/15321819.2025.2505033\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Health Professions\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of immunoassay & immunochemistry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/15321819.2025.2505033","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Health Professions","Score":null,"Total":0}
Prognostic significance of B-Catenin and E-Cadherin expression in gastric carcinoma.
Introduction: Gastric cancer (GC) is a leading cause of cancer-related mortality worldwide. Dysregulation of molecular pathways, including β-Catenin-mediated Wnt signaling, epithelial-to-mesenchymal transition (EMT), and E-Cadherin-modulated cell adhesion, plays critical roles in gastric carcinogenesis. This study assesses the expression patterns of β-Catenin and E-Cadherin in GC and explores their prognostic significance.
Methods: This retrospective, multi-center study analyzed GC cases diagnosed between 2009 and 2019 at the pathology departments of Security Forces and Rabta Hospitals. Tissue microarray (TMA) paraffin blocks from 48 GC cases were immunohistochemically stained using antibodies for β-Catenin (Leica, 17C2) and E-Cadherin (Leica, 36B5). β-Catenin expression was scored as membranous, cytoplasmic, or nuclear, with overexpression defined as ≥ 50% positive cells. E-Cadherin staining was categorized from absent (score 0) to marked membranous staining (score 3), with scores 0-2 considered aberrant. Statistical analysis was performed using SPSS version 23.
Results: Of the 48 cases, β-Catenin overexpression was observed in 50% of cases, significantly associated with tumor differentiation (p = 0.033), age > 60 years (p = 0.042), and male sex (p = 0.028). Aberrant E-Cadherin expression was found in 65% of cases, linked to poorly cohesive and diffuse subtypes (p = 0.053), poor differentiation (p = 0.042), and recurrence (p = 0.043), with a trend toward reduced survival (p = 0.056).
Conclusion: β-Catenin overexpression and aberrant E-Cadherin expression are frequent in GC, reflecting their roles in tumor progression via Wnt signaling and EMT. These findings highlight their potential as prognostic biomarkers and therapeutic targets, particularly for Wnt pathway-directed therapies in personalized GC management.
期刊介绍:
The Journal of Immunoassay & Immunochemistry is an international forum for rapid dissemination of research results and methodologies dealing with all aspects of immunoassay and immunochemistry, as well as selected aspects of immunology. They include receptor assay, enzyme-linked immunosorbent assay (ELISA) in all of its embodiments, ligand-based assays, biological markers of ligand-receptor interaction, in vivo and in vitro diagnostic reagents and techniques, diagnosis of AIDS, point-of-care testing, clinical immunology, antibody isolation and purification, and others.